USD 0.16
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.91 Million USD | -60.83% |
2022 | 4.89 Million USD | -66.36% |
2021 | 14.56 Million USD | -31.08% |
2020 | 21.12 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 845.44 Thousand USD | -24.82% |
2024 Q1 | 1.12 Million USD | -41.39% |
2023 Q3 | 2.96 Million USD | 884.27% |
2023 Q2 | 301.41 Thousand USD | 48831.01% |
2023 FY | 1.91 Million USD | -60.83% |
2023 Q1 | 616.00 USD | -99.99% |
2022 FY | 4.89 Million USD | -66.36% |
2022 Q2 | 3.73 Million USD | -66.57% |
2022 Q1 | 11.16 Million USD | -23.34% |
2022 Q4 | 4.89 Million USD | -5.97% |
2022 Q3 | 5.2 Million USD | 39.58% |
2021 Q3 | 15.1 Million USD | -11.53% |
2021 Q1 | 14.59 Million USD | 0.0% |
2021 FY | 14.56 Million USD | -31.08% |
2021 Q4 | 14.56 Million USD | -3.58% |
2021 Q2 | 17.07 Million USD | 16.94% |
2020 FY | 21.12 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Danimer Scientific, Inc. | 452.26 Million USD | 99.576% |
Vystar Corporation | 9.75 Million USD | 80.327% |